SBIR/STTR Research Award

Non-invasive Blood Alcohol Sensor for Emergency Room Applications

Award identifier 06c976c7561aa59e4988aa5c2976f100a83512353345d4cc570861b1a5e2a584Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,998

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
UES INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
FV5WK6YTN215
Solicitation number
PA12-088
Topic code
NIGMS

Research abstract

DESCRIPTION (provided by applicant): Measurements of cell viability (percentage live versus dead cells) may be used to evaluate: cellular damage due to toxins, the effect of infection, response to drugs, toxicity during early stages of drug development, the life of cancerous cells, the rejection of implanted organs, etc. There is a need to focus on label-free approaches to drug discovery, especially regarding hit identification (focused screening and primary screening/HTS) and lead optimization. Identifyinghits generally requires analysis of cell population viability under drug treatment. Early stages of drug discovery rely on screening large numbers of compounds to analyze their toxic effects on cells. These results are based on biochemical assays performed in an ultra high throughput format. First and foremost is the cell viability analysis, i.e., to recognize the live and dead cells in a population of cells treated by various compounds at different concentration levels. Cell death can occur in many ways:apoptosis, autophagy, cornification and necrosis, to name a few. The underlying biochemical causes responsible for events resulting in different kinds of cell deaths are beginning to be better understood. Although cell morphology and significant ultrastructural changes occur during the initiation and progress of cell death, most of the current protocols to identify dead cells and the death mechanism depend on some form of labeling, such as fluorescence. Disadvantages in using labels for viability analysisinclude difficulty in delivering the dye to the target, keepingthe dye passive, unknown response to high frequency light, unknown response to dye perturbation over a long period, etc. Also, conducting high throughput studies using fluorescent dyes is expensive and requires complex robotics to prepare specimens. The proposed Cell Analytics for Viability Experiments (CAVETM) system would be a significant step forward in achieving label-free, accurate experiments in life sciences and drug discovery for label free viability analysis and hit-analysis. Label-free techniques work in the absence of fluorescence markers; hence, they do not possess the disadvantages of using fluorescent labels. This is also amenable to the study of cells using video microscopy and time-lapse microscopy. The ability to directly measure the morphological and ultra-structural changes of the cell components and relate the changes to cell death phenomena could open up the drug discovery world to the label-free, live primary cell monitoringexperiments. In Phase 1, we plan to accomplish complete software development for detecting apoptosis induced cell death using a label-free process. This includes novel mechanisms to segment label-free cells in a dense cell population, measure a large number of features, automatic assay dependent feature selection, and classification of live and dead cells. In Phase 2, viability analysis will be expanded to other forms of cell death induction such as necrosis, autophagy, cornification, etc. and will developinformatics support to predict cell death based on initial cell features. The whole cell viability analysis will also be extended to 2D+T (time) data in the form of time-lapse or video data of live cells. We plan to market the software through our tie ups with microscopy vendors, UC drug discovery center and by directly providing customized services. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Transitioning cell-based assays to label-free systems has significant potential to streamline, improve, and reduce cost for drug discovery. Two drug discovery steps where the label-free approach will be significant are hit identification (focused screening and primary screening/HTS) and lead compound optimization. Identifying hits requires analysis ofcell population viability under drug treatment, including screening a large number of compounds to analyze toxic effects on cells using defined biochemical assays in an ultra-high throughput format. Foremost is cell viability, i.e., recognition of live vs. dead cells treated by various compounds at different concentrations. Cell death occurs in many ways: apoptosis, autophagy, cornification and necrosis to name a few. Biochemical causes for events resulting in different kinds of cell death are beginning to be deciphered. Although cell morphology and significant ultra-structural changes occur during initiation and progress of cell death, most current protocols to identify dead cells and death mechanism depend on some form of labeling, fluorescent or otherwise. There are several disadvantages in using labeled viability analysis. First, difficulty in delivering dyes to targets or requirement to deliver it via DMSO or other solvent, which may have additional effects on cells. Second, ensuring dyes are passive to cells or subcellular locations, in that the dyes do not cause an effect, especially over long incubation times. Third, repeated exposure of cells to high frequency light to monitor progression of cell death and/or cellular assay being monitored. In addition to concerns regarding effect of dyes within cells, conducting hi

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

294 SBIR/STTR records share this UEI (1983–2023). Reported award amounts total $73,979,003. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, Department of Energy, National Science Foundation, National Aeronautics and Space Administration, Department of Health and Human Services, Nuclear Regulatory Commission

Contractor profile

UES, INC.

Historical federal award activity, when published, is on that contractor profile. Matched by UEI only.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.